Add BrightSurf on Google Email

Gut microbes spur development of bowel cancer

A study published in The Journal of Experimental Medicine reveals that gut microbes contribute to the development of intestinal tumors, leading to colorectal cancer. Disrupting gut bacteria with antibiotics prevented polyp formation in mice, suggesting a link between inflammation and tumor growth.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·DateMar 3, 2014

Simple, at-home test will detect most colorectal cancers

A new evidence review finds that fecal immunochemical tests (FITs) detect about 79% of colorectal cancers and correctly identify 94% of patients without cancer. The test is simple, can be done at home, and can save lives, making it a great tool for assessing which patients have cancer and which do not.

SourceKaiser Permanente·JournalAnnals of Internal Medicine·DateFeb 3, 2014

Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer

A University of Colorado Cancer Center study found that ALK and ROS1 gene rearrangements, known to drive subsets of lung cancer, are also present in some colorectal cancers. This implies that drugs used to target ALK and ROS1 in lung cancer may have applications in treating a subset of colorectal cancer patients.

SourceUniversity of Colorado Anschutz Medical Campus·JournalMolecular Cancer Research·DateDec 17, 2013

Decreased diversity of bacteria microbiome in the gut is associated with risk of colorectal cancer

A new study found that decreased bacterial diversity in the gut is associated with an increased risk of colorectal cancer. The research, published in the Journal of the National Cancer Institute, suggests that a reduced variety of gut microbiota may contribute to the development of CRC.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateDec 6, 2013

Nuclear medicine therapy increases survival for patients with colorectal cancer liver metastases

New research published in The Journal of Nuclear Medicine found that radioembolization therapy can extend survival for patients with colorectal cancer liver metastases by approximately 50 percent. This treatment option has shown promise as a life-extending treatment for salvage patients who have failed current treatments.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 6, 2013

MUHC researchers identify biomarkers that could lead to early diagnosis of colorectal cancer

Researchers at the McGill University Health Centre have identified genetic changes in the colon lining that could be used as biomarkers for early diagnosis of colorectal cancer. The study, published online in Cancer Prevention Research, has implications for the nearly one million people diagnosed annually worldwide.

SourceMcGill University Health Centre·JournalCancer Prevention Research·DateOct 30, 2013

Colonoscopy screening every ten years could prevent 40% of colorectal cancers

A large study found that colonoscopy screening can prevent up to 40% of colorectal cancers, with more frequent intervals recommended for those with a personal history of adenoma or family history of colorectal cancer. The study also suggests that sigmoidoscopy alone is insufficient for reducing the incidence of proximal colon cancer.

SourceHarvard T.H. Chan School of Public Health·JournalNew England Journal of Medicine·DateSep 18, 2013

Hybrid screening strategy emerges for colorectal cancer

A new study suggests a hybrid screening strategy that combines annual or biennial fecal immunological tests with a single colonoscopy at age 66 may reduce colorectal cancer incidence and mortality while lowering costs. This approach can deliver health benefits comparable to current strategies, making it an attractive alternative.

SourceAmerican Gastroenterological Association·JournalClinical Gastroenterology and Hepatology·DateAug 27, 2013

Novel RNA-based classification system for colorectal cancer

A novel transcriptome-based classification of colon cancer has been developed, improving disease stratification based on clinicopathological variables and common DNA markers. The analysis identified six molecular subtypes associated with distinct clinical and pathological characteristics.

SourcePLOS·JournalPLOS Medicine·DateMay 21, 2013

Cancer survivors battle with the blues

Depressive symptoms observed in cancer survivors between one and ten years after diagnosis increase the risk of premature death. Cancer survivors with depression are twice as likely to have died early compared to those without depression.

SourceSpringer·JournalJournal of Cancer Survivorship·DateMay 16, 2013

Adding cetuximab to chemotherapy enables select patients with advanced colorectal cancer and liver metastasis to undergo surgery, extending survival by several months

A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateApr 8, 2013